A nationwide clinical trial for the National Cancer Institute, featuring research by a USF doctor, recently published its findings in the New England Journal of Medicine.
The University of South Florida was one of 21 cites contributing to the fight against skin cancer through a comprehensive nationwide study sponsored by the National Cancer Institute.
Dr. Douglas Reintgen, professor of surgery at
USF Health, was the local principal investigator for the study, which tested a vaccine for advanced melanoma supplemented by immunotherapy drug interleukin-2.
Results of the study were recently published in the New
England Journal of Medicine.
Read the complete
article.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.